Skip to main content

Written question asked by Melanie Johnson (Labour) on Friday, 24 October 1997, in the House of Commons. It was due for an answer on Wednesday, 29 October 1997. It was answered by Baroness Jowell (Labour) on Wednesday, 29 October 1997 on behalf of the Department of Health.


Dept of Health

Question
Statement on Department's policy in respect of screening for, and treatment of, Hepatitis C.
Answer

Miss Melanie Johnson: To ask the Secretary of State for Health what is his Department's policy in respect of screening for, and treatment of, hepatitis C. [12300] Ms Jowell: Blood donations have been screened for antibodies to hepatitis C virus since September 1991 when reliable tests first became available. Recipients of blood or blood components donated before that date from donors since found to be carriers of hepatitis C virus are being traced in order to provide counselling, testing and specialist referral as appropriate. Organs and tissue, resulting from either live or cadaveric donations, are also screened for hepatitis C. Injecting drug misusers who share contaminated equipment are at increased risk of acquiring hepatitis C infection. The guidance to purchasers of drug treatment and care services, which the Department issued in March 1997, included advice for purchasers on dealing with those who seek testing for hepatitis C. The Guidelines for Doctors on the Clinical Management of Drug Misusers last issued in 1991 are currently being revised and will be published next year. They will include updated advice on the management of hepatitis C in drug misusers. There is a need to increase knowledge about the natural history, prevalence, transmission and treatment of hepatitis C so that the National Health Service is equipped to deliver services based on the best scientific advice available about the disease. In 1996, the Department made £1 million available for research in these areas. The results of the research commissioned so far will become available over the next three years. A further £500,000 will be allocated this year to expand the research programme. In addition, the NHS Health Technology Assessment is considering research proposals to establish the effectiveness of the early treatment of chronic hepatitis C with alpha interferon. The NHS Executive is funding the Royal College of Physicians to facilitate the development of clinical guidelines on the appropriate use of alpha interferon in patients with hepatitis C.


Secondary information

Type
Written question
Reference
12300; 299 c826-7W
Session
1997-98
Subjects
Counselling Hepatitis Medical treatments Screening